Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by British Columbia Cancer Agency.
Recruitment status was  Recruiting
BC Cancer Foundation
Information provided by (Responsible Party):
British Columbia Cancer Agency
ClinicalTrials.gov Identifier:
First received: October 30, 2012
Last updated: NA
Last verified: October 2012
History: No changes posted
This is a pilot study that aims to develop a lung cancer screening program for workers in British Columbia, Canada exposed to asbestos who are at risk of developing lung cancer/pleural mesothelioma. This is high risk population is at of respiratory system diseases as a result of their occupational exposures. Additionally, knowledge garnered from this study will allow us to develop other studies that will further our understanding of asbestos related lung cancer and mesothelioma.

Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos

Resource links provided by NLM:

Further study details as provided by British Columbia Cancer Agency:

Primary Outcome Measures:
  • Development of Model to Predict Workers at highest risk of lung cancer/mesothelioma [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: October 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Workers exposed to asbestos


Ages Eligible for Study:   50 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Workers in British Columbia who have been exposed to asbestos.

Inclusion Criteria:

  • Women or men age 50 to 79 years
  • history of exposure to asbestos at work and one or more of the following:

    • lung cancer risk ≥2% over 3 years or
    • asbestosis or pleural plaques on a chest x-ray or
    • abnormal auto-antibodies level using the EarlyCDT test
  • Capable of providing informed consent for screening procedures (low dose spiral CT, lung function, blood biomarkers).

Exclusion Criteria:

  • Any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), acute or chronic respiratory failure, or any disorder, that in the opinion of the physician unlikely to benefit from screening due to shortened life-expectancy from co-existing illnesses
  • Have been previously diagnosed with mesothelioma
  • Have had other cancer within the past 5 years with the exception of the following cancers: non-melanomatous skin cancer,localized prostate cancer, carcinoma in situ (CIS) of the cervix, or superficial bladder cancer. Treatment of the exceptions must have ended >6 months before registration into this study
  • Pregnancy
  • Unwilling to have a low dose CT scan of chest
  • Unwilling to sign a consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01719068

Contact: Sharon Gee 604-675-8089 sgee@bccancer.bc.ca

Canada, British Columbia
British Columbia Cancer Agency Recruiting
Vancouver, British Columbia, Canada, V5Z1L3
Contact: Sharon Gee    604-675-8089    sgee@bccancer.bc.ca   
Principal Investigator: Stephen Lam, MD         
Sub-Investigator: Annette McWilliams, MD         
Sub-Investigator: Tawimas Shaipanich, MD         
Sponsors and Collaborators
British Columbia Cancer Agency
BC Cancer Foundation
Principal Investigator: Stephen Lam British Columbia Cancer Agency
  More Information

Responsible Party: British Columbia Cancer Agency
ClinicalTrials.gov Identifier: NCT01719068     History of Changes
Other Study ID Numbers: H12-01812 
Study First Received: October 30, 2012
Last Updated: October 30, 2012
Health Authority: Canada: Ethics Review Committee

Keywords provided by British Columbia Cancer Agency:
Lung Cancer
Early Detection

Additional relevant MeSH terms:
Lung Neoplasms
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on May 24, 2016